Parse Biosciences’ Post

Learn about how to widen the therapeutic window for T-cell engagers using platform technologies. See our CD3 x PSMA case study at Antibody Engineering & Therapeutics #AETEU

Are you heading to Festival of Biologics? Be sure to stop by my poster to learn more about new mouse strains that can be used to evaluate antibody-based therapeutics!

We are excited to share the successful progression of our partnership with Parse Biosciences, resulting in the first-ever use of Evercode Mouse BCR for B cell analysis of transgenic mice. Read the press release and connect with us at the Antibody Engineering & Therapeutics (AET) conference in San Diego to learn why the highest-quality drug developers and technology innovators are partnering with AbTherx. https://lnkd.in/e_gPuzt4 #abtherx #transgenicmice #innovation #partnership

Introducing our latest scientific poster on a one-stop, integrated in vitro platform designed to streamline therapeutic development. In this poster, we showcase our extensive expertise in lead characterizations: • ADC: Internalization, cytotoxicity & bystander killing, and plasma stability assays. • TCE: T cell killing, activation and cytokine release assays. • Autoimmune & inflammation molecules: Ligand competitive binding, reporter gene and proliferation assays. Learn how these comprehensive assays can contribute to more effective biologics drug discovery and development. View the full poster here: ▶️ https://lnkd.in/erdKY9tW #ScientificPoster #AntibodyTherapeutic #TherapeuticDevelopment #Drugdevelopment

Merus announced interim clinical data as of a data cutoff of March 6, 2024, from the ongoing Phase 1/2 trial of the bispecific antibody Petosemtamab in combination with Pembrolizumab. During the discovery process of Petosemtamab, Merus successfully utilized the tumor organoid platform from our portfolio company Crown Bioscience for target validation, antibody screening, and mechanistic studies. This breakthrough organoid research has significantly shortened the time from initial discovery to clinical trials to just five years. Moreover, Petosemtamab demonstrated more sensitive efficacy in organoids compared to traditional cell lines and PDX animal models, validating the advantages of 3D in vitro tumor organoid models in drug discovery. #MedicalInnovation #CancerResearch #ClinicalTrials #BispecificAntibody #OrganoidTechnology #QimingHealthcare #QimingPortfolio

Learning about SPR with our lovely Alto (https://lnkd.in/dwmBcwB8) developed by Nicoya - it has such a wide range of applications: - Antibody Drug Conjugates (#ADCs): Conjugating highly toxic therapeutics to antibodies is great because their effect is more constrained to the target tissues. But what is the effect of conjugation on the Kd antibody-antigen? - #Antibody development: measuring not only binding constants but also kinetics Kon/Koff - #Immunotherapy: #CART and #TCR therapeutics are already making a difference to some cancer patients and hold huge promise for the future. Really important to measure protein-protein interaction between cell receptors. - #Aptamers: Amazing that by optimising the primary sequence with just 4 bases - A, T, G, C - you can tune oligos to selectively bind antigens. - #PROTAC and other molecular glues that trigger protein-protein interactions The Alto is a user-friendly, benchtop SPR. It fits in tiny spaces, in Merrow Scientific Ltd lab we just had a free corner, and was enough! Thanks to Digital Microfluidics, it will just require minimal samples and everything happens in disposable cartridges. No tubing, no blockings, no cross-contamination, no post-analysis maintenance!

Coeptis Therapeutics’ science is built on the notion that cell therapies should be safe, effective, and available for everyone. Dive into the advantages of NK cells as #immunotherapy and our program here: https://bit.ly/3UukbZt #Biotech #CancerResearch #Innovation #Biopharma #StemCells

What Innovations Could Help Us Overcome Preclinical Model Limitations For RNA-LNPs? https://lnkd.in/e9HvnJxZ In this Advancing RNA Live clip, Biontech’s Professor Ben Muir and Hopewell Therapeutics, Inc.’s Kate Zhang share their perspectives on the most exciting novel screening methods, innovative preclinical models, and next-gen technologies they hope can/will eventually help us bridge the translation gap between preclinical models and the clinic.

In search of that winning antibody-drug conjugate (ADC) combination within a 3D tumor microenvironment? Would this application note help?  Describes 3D advanced cell models, such as spheroids or organoids, to assess in vitro drug effects with the iQue®️ High-Throughput Screening (HTS) by Cytometry Platform.  Learn more on measurements of target cell counts and viability to assess in vitro drug effects: https://ow.ly/9Q0q50SGSKk #highthroughputscreening #screening #highthroughput #antibodydrugconjugates #ADCs #spheroids #3Dcell #cytotoxicity

Heading to ISCT 2024? Our agenda is jam-packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/eaQuHziT